By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Agendia BV 

Slotervaart Medical Centre, 9D
Louwesweg 6
Amsterdam    1066 EC  The Netherlands
Phone: 31-20-512-9161 Fax: 31-20-512-9162


SEARCH JOBS


Industry
Services
Healthcare






Company News
Agendia BV’s Mammaprint And Blueprint Tests Highlighted In Multiple Presentations At The 2016 San Antonio Breast Cancer Symposium, Adding Further Clinical Utility 12/2/2016 9:03:18 AM
Agendia BV's Proven Breast Cancer Recurrence Assay, MammaPrint, Now Available In The Middle East 11/8/2016 10:01:23 AM
Agendia BV Announces The Award Of A New Category 1 CPT Code From American Medical Association For The Mammaprint 70-Gene Breast Cancer Recurrence Assay 11/2/2016 8:52:46 AM
Agendia BV Expands Its Business Activities In Germany 10/26/2016 9:08:30 AM
Agendia BV Appoints Three Leading Cancer Physicians To Its Medical Advisory Board 10/17/2016 12:04:22 PM
Agendia BV Release: The New England Journal of Medicine Publishes MINDACT Trial Results Proving The Clinical Utility Of Mammaprint In Assisting Physicians To Identify Early-Stage Breast Cancer Patients Who Can Safely Forgo Chemotherapy 8/25/2016 8:49:21 AM
Agendia BV’s Mammaprint First And Only Genomic Assay To Receive Level 1A Clinical Utility Evidence For Chemotherapy Benefit In Early Breast Cancer Patients 4/19/2016 10:52:22 AM
Agendia BV To Highlight New MammaPrint Data At The 2016 European Breast Cancer Conference As A Prelude To Upcoming MINDACT Trial Findings 3/8/2016 10:34:04 AM
Agendia BV And Partners Receive $6.8 Million From European Commission (EC) To Study Targeted Therapies For Colorectal Cancer 12/16/2015 8:16:51 AM
Agendia BV Highlights Study Showing MammaPrint/BluePrint Tests Predict Response To Current Breast Cancer Chemotherapy And Targeted Therapy Regimens 9/29/2015 11:03:21 AM
12345678910...
//-->